Skip to content

H.R. 2821 · 119th Congress (2025–2027)

FDA Modernization Act 3.0

This bill requires the Food and Drug Administration (FDA) to publish an interim final rule implementing a provision of the Consolidated Appropriations Act of 2023 that authorized the use of certain alternatives to animal testing to support investigational use of a new drug.

The rule must replace references to animal tests, data, studies, models, and research with references to nonclinical tests, data, studies, models, and research throughout the FDA’s regulations governing investigational new drug applications.

The rule must be published within one year of the bill’s enactment, and must take immediate effect as an interim final rule.

Show official title

To require the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to publish a final rule relating to nonclinical testing methods.

Passed House

This bill’s path

466 days after it was introduced

This is H.R. 2821’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced15 months

  2. Passed House

  3. Passed Senate

  4. Sent to President

  5. Signed into law

Sponsor
Rep. Earl L. "Buddy" Carter (R-GA-1)
Cosponsors
41 cosponsors

5 original · 36 later

20 R · 21 D

  1. Rep. Vern Buchanan (R-FL-16)· Original · Apr 10, 2025
  2. Rep. Nanette Diaz Barragán (D-CA-44)· Original · Apr 10, 2025
  3. Rep. Troy A. Carter (D-LA-2)· Original · Apr 10, 2025
  4. Rep. Rosa L. DeLauro (D-CT-3)· Original · Apr 10, 2025
  5. Rep. Diana Harshbarger (R-TN-1)· Original · Apr 10, 2025
  6. Rep. Lloyd Doggett (D-TX-37)· Later · Apr 14, 2025
  7. Rep. Dan Crenshaw (R-TX-2)· Later · Apr 17, 2025
  8. Rep. Mike Carey (R-OH-15)· Later · Apr 17, 2025
  9. Rep. Brian K. Fitzpatrick (R-PA-1)· Later · Apr 17, 2025
  10. Rep. Nicole Malliotakis (R-NY-11)· Later · Apr 17, 2025
  11. Rep. Jerrold Nadler (D-NY-12)· Later · Apr 17, 2025
  12. Rep. Judy Chu (D-CA-28)· Later · Apr 29, 2025
  13. Rep. Daniel S. Goldman (D-NY-10)· Later · Apr 29, 2025
  14. Rep. Darren Soto (D-FL-9)· Later · Apr 29, 2025
  15. Rep. Hillary J. Scholten (D-MI-3)· Later · Apr 29, 2025
  16. Rep. Jay Obernolte (R-CA-23)· Later · May 13, 2025
  17. Rep. Josh Gottheimer (D-NJ-5)· Later · May 20, 2025
  18. Rep. Jason Crow (D-CO-6)· Later · Jun 6, 2025
  19. Rep. Ted Lieu (D-CA-36)· Later · Jun 27, 2025
  20. Rep. Christopher H. Smith (R-NJ-4)· Later · Jul 2, 2025
  21. Rep. Claudia Tenney (R-NY-24)· Later · Jul 2, 2025
  22. Del. Eleanor Holmes Norton (D-DC)· Later · Jul 10, 2025
  23. Rep. Maria Elvira Salazar (R-FL-27)· Later · Jul 10, 2025
  24. Rep. Lois Frankel (D-FL-22)· Later · Jul 14, 2025
  25. Rep. Josh Harder (D-CA-9)· Later · Jul 14, 2025
  26. Rep. David G. Valadao (R-CA-22)· Later · Jul 14, 2025
  27. Rep. Gus M. Bilirakis (R-FL-12)· Later · Jul 16, 2025
  28. Rep. Scott Fitzgerald (R-WI-5)· Later · Jul 16, 2025
  29. Rep. Laurel M. Lee (R-FL-15)· Later · Jul 17, 2025
  30. Rep. Ken Calvert (R-CA-41)· Later · Jul 22, 2025
  31. Rep. Eugene Simon Vindman (D-VA-7)· Later · Sep 11, 2025
  32. Rep. Mark Pocan (D-WI-2)· Later · Nov 4, 2025
  33. Rep. Michael Lawler (R-NY-17)· Later · Nov 20, 2025
  34. Rep. Randy K. Weber, Sr. (R-TX-14)· Later · Dec 2, 2025
  35. Rep. Joe Neguse (D-CO-2)· Later · Dec 11, 2025
  36. Rep. Raja Krishnamoorthi (D-IL-8)· Later · Dec 15, 2025
  37. Rep. Thomas H. Kean, Jr. (R-NJ-7)· Later · Jan 7, 2026
  38. Rep. Julie Johnson (D-TX-32)· Later · Jan 15, 2026
  39. Rep. Young Kim (R-CA-40)· Later · Apr 22, 2026
  40. Rep. Nicholas A. Langworthy (R-NY-23)· Later · May 12, 2026
  41. Rep. Shri Thanedar (D-MI-13)· Later · Jun 2, 2026
Policy area
Health
Subjects
  • Administrative law and regulatory procedures
  • Department of Health and Human Services
  • Drug safety, medical device, and laboratory regulation
  • Medical research
  • Research administration and funding

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in House

    Document: Introduced in House

    Sources
  2. ▸ 7 committee actions · Apr 10, 2025 – Jun 18, 2026
    1. Referred to committee

      Referred to the House Committee on Energy and Commerce.

      Sources
    2. Referred to Health

      Referred to the Subcommittee on Health.

      Sources
    3. Subcommittee markup session held

      Subcommittee Consideration and Mark-up Session Held

      Sources
    4. Forwarded by subcommittee

      Forwarded by Subcommittee to Full Committee by Voice Vote.

      Sources
    5. Markup session held

      Committee Consideration and Mark-up Session Held

      Sources
    6. Ordered reported

      Ordered to be Reported by the Yeas and Nays: 44 - 0.

      Sources
    7. Reported by committee

      Reported by the Committee on Energy and Commerce. H. Rept. 119-706.

      Sources
  3. Latest

    Passed House

    Congressional Record H4639

    On motion to suspend the rules and pass the bill Agreed to by voice vote.

    The House passed the bill.

    Document: Engrossed in House

    Sources

Committees

  1. HouseEnergy and CommerceReferred Apr 10, 2025 · Markup May 21, 2026 · Reported Jun 18, 2026H. Rept. 119-706
    1. H. Rept. 119-706 · Jun 18, 2026 · Fda Modernization Act 3.0
  2. HouseHealthReferred Apr 10, 2026 · Markup May 13, 2026 · Reported May 13, 2026
    1. May 13, 2026 · Markup

    2. Jul 16, 2025 · Hearing

    3. Jul 9, 2025 · Hearing

Floor record

i

Explicit consideration evidence: the measure’s bill-status citation matched a GovInfo title, headline, or first paragraph. Incidental mentions are not listed.

  1. Jul 20, 2026 · House · Considered under suspension of the rulesCongressional Record H4639–H4640

    Fda Modernization Act 3.0

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Reported in House
Engrossed in House
Titles (2)
  1. FDA Modernization Act 3.0

    Display title, Short title · Engrossed in House, Reported in House, Introduced in House

  2. To require the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to publish a final rule relating to nonclinical testing methods.

    Official title · Engrossed in House, Introduced in House